Zinbryta

Product NDC: 0074-0034
11-digit product format: 000740034
Labeler code: 0074
Product ID: 0074-0034_44238333-9880-413b-9a9e-1f2b09e0fd6a
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Daclizumab
Dosage form: INJECTION, SOLUTION
Route: SUBCUTANEOUS
Labeler: Abbvie
Application: BLA761029
Marketing category: BLA
Marketing start: 2017-05-26
Marketing end: 2019-10-31
Substance: DACLIZUMAB
Active strength: 150 mg/mL
Pharmacologic classes: Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC]
NDC exclude flag: No
Listing certified through: 0000-00-00
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	0074-0034		D	Discontinued by firm		2026-07-31
excluded package	package	0074-0034	0074-0034-01	D	Discontinued by firm		2026-07-31

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761029	Zinbryta	daclizumab	351(a)	Disc	2026-06-01